The ISFTD presentation on October 11, 2026 is the next key catalyst — positive biomarker data could drive a re-rating for this small-cap biotech. However, the company needs a strategic partner for Phase 3 DLB, and cash runway is not disclosed; monitor for partnership news and the ALS trial initiation in Q4 2026.
Price Chart
Executive Summary
CervoMed announced that neflamapimod will be featured in a late-breaking oral presentation at the ISFTD Annual Meeting in October 2026, highlighting 12-week biomarker data (NfL and GFAP) from at least 22 participants in its Phase 2a nfvPPA trial. The company also completed enrollment in the trial (25 participants) and noted FDA alignment on a registration path for DLB, though it is seeking a strategic partner for Phase 3. This is a pipeline update with no financial data or regulatory decision, making it a modest positive catalyst event for a clinical-stage biotech with no approved products and a $38M market cap.
Key Facts
- CervoMed completed enrollment in Phase 2a nfvPPA trial of neflamapimod (25 participants).
- Late-breaking oral presentation at ISFTD (Oct 11, 2026) will show 12-week biomarker data (NfL, GFAP) from at least 22 participants.
- Neflamapimod granted Orphan Drug Designation by FDA for FTD in 2024.
- Company is focused on finding a strategic partner to advance neflamapimod into Phase 3 for DLB after FDA alignment on registration path.
- First patient expected to be dosed in EXPERTS-ALS Phase 2a trial in Q4 2026.
- No approved treatments exist for nfvPPA in the U.S. or EU; estimated 10,000-15,000 patients in U.S. and 15,000-20,000 in EU.
Financial Impact
No financial data provided; company is pre-revenue clinical-stage with $38M market cap.
Risk Factors
- No approved products; entirely dependent on clinical trial success and partnership funding.
- Biomarker data from 22 participants is early-stage and may not predict Phase 3 outcomes.
- Company may need to raise capital if a strategic partner is not secured, causing dilution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3359388 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K | $2.25 $2.24 | ▼ −0.44% | ▲ +0.66% | $2.22 (−1.33%) |
Oct 13, 2026 14d ago | 8-K | $2.27 $2.29 | ▲ +0.88% | ▲ +1.96% | $2.22 (−2.20%) |
Oct 9, 2026 17d ago | 8-K | $2.51 $2.27 | ▼ −9.56% | ▼ −9.55% | $2.22 (−11.55%) |
Sep 10, 2026 6w ago | Press Release | $2.48 $2.57 | ▲ +3.63% | ▲ +2.78% | $2.22 (−10.48%) |
Aug 10, 2026 11w ago | 8-K | $3.09 $3.07 | ▼ −0.65% | ▼ −0.90% | $2.22 (−28.16%) |
Aug 4, 2026 12w ago | 8-K | $2.80 $2.81 | ▲ +0.36% | ▲ +0.56% | $2.22 (−20.71%) |
Aug 4, 2026 12w ago | Press Release | $2.80 $2.81 | ▲ +0.36% | ▲ +0.56% | $2.22 (−20.71%) |
Jul 13, 2026 15w ago | EFFECT | $3.31 $3.08 | ▲ +6.95% | ▲ +7.30% | $2.22 (+32.93%) |
Jul 6, 2026 16w ago | S-3 | $3.42 $3.41 | ▲ +0.29% | ▼ −0.02% | $2.22 (+35.09%) |
Jun 22, 2026 18w ago | 8-K | $3.72 $3.26 | ▲ +12.37% | ▲ +12.32% | $2.22 (+40.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers